Updates of primary central nervous system lymphoma
Open Access
- 1 January 2024
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 15
Abstract
Lymphoma occurring in the central nervous system is considered primary central nervous system lymphoma (PCNSL), usually without systematic lesions. Over the last few decades, a deep understanding of PCNSL has been lacking due to the low incidence rate, and the overall survival and progression-free survival of patients with PCNSL are lower than those with other types of non-Hodgkin lymphoma. Recently, there have been several advancements in research on PCNSL. Advances in diagnosis of the disease are primarily reflected in the promising diagnostic efficiency of novel biomarkers. Pathogenesis mainly involves abnormal activation of nuclear factor kappa-B signaling pathways, copy number variations, and DNA methylation. Novel therapies such as Bruton’s tyrosine kinase inhibitors, immunomodulatory drugs, immune checkpoint inhibitors, and phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors are being evaluated as possible treatment options for PCNSL, especially for relapsed/refractory (R/R) cases. Several clinical trials also indicated the promising feasibility and efficacy of chimeric antigen receptor T-cell therapy for selected R/R PCNSL patients. This review focuses on discussing recent updates, including the diagnosis, pathogenesis, and novel therapy of PCNSL.Keywords
Funding Information
- National Center for Special Education Research, Institute of Education Sciences (R324N180020)
This publication has 129 references indexed in Scilit:
- Targetable genetic features of primary testicular and primary central nervous system lymphomasBlood, 2016
- Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System LymphomasClinical Cancer Research, 2015
- Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomasNeuropathology and Applied Neurobiology, 2015
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's LymphomaNew England Journal of Medicine, 2015
- Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphomaNeurology, 2015
- CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphomaBlood, 2013
- Recurrent Mutations of MYD88 and TBL1XR1 in Primary Central Nervous System LymphomasClinical Cancer Research, 2012
- Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous systemBlood, 2011
- Array-based DNA methylation profiling of primary lymphomas of the central nervous systemBMC Cancer, 2009
- High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trialThe Lancet, 2009